Prolonged Tumor Retention of a Human Diabody Targeting HER2/neu
Author Information
Author(s): GP Adams, R Schier, AM McCall, RS Crawford, EJ Wolf, LM Weiner, JD Marks
Primary Institution: Fox Chase Cancer Center; University of California, San Francisco
Hypothesis
Can diabody molecules improve the delivery of therapeutic agents to tumors?
Conclusion
The C6.5 diabody format provides a significant advantage in tumor targeting compared to the scFv monomer.
Supporting Evidence
- The C6.5 diabody showed a 40-fold increase in affinity for HER2/neu compared to the scFv.
- Diabody retention in tumors was significantly higher than in blood and normal tissues.
- At 4 hours post-injection, the diabody retained 10.1 %ID g-1 in tumors.
- Diabody showed a slower elimination phase from circulation compared to the scFv.
- Significantly more diabody was retained in tumors than in any other organ at all time points studied.
Takeaway
This study shows that a special type of antibody called a diabody can stick to tumors longer than regular antibodies, which might help deliver medicine better.
Methodology
The study involved creating a diabody from a specific scFv and testing its retention in tumor-bearing mice using biodistribution studies.
Limitations
The study primarily focused on one type of tumor and may not generalize to all cancers.
Participant Demographics
Six- to eight-week-old CB. 17 Icr scid mice bearing human ovarian carcinoma SK-OV-3 cells.
Statistical Information
P-Value
0.00043
Statistical Significance
p<0.001
Want to read the original?
Access the complete publication on the publisher's website